Currently out of the existing stock ratings of Brian Cheng, 91 are a BUY (81.25%), 5 are a SELL (4.46%), 16 are a HOLD (14.29%).

Brian Cheng

Work Performance Price Targets & Ratings Chart

Analyst Brian Cheng, currently employed at JPMORGAN, carries an average stock price target met ratio of 45.67% that have a potential upside of 23.37% achieved within 99 days.

Brian Cheng’s has documented 210 price targets and ratings displayed on 28 stocks. The coverage is on Healthcare, Utilities sectors.

Most recent stock forecast was given on IMVT, Immunovant at 04-Aug-2026.

Wall Street Analyst Brian Cheng

Analyst best performing recommendations are on CRGX (CARGO THERAPEUTICS, COMMON STOCK).
The best stock recommendation documented was for PTGX (PROTAGONIST THERAPEUTICS) at 3/4/2025. The price target of $57 was fulfilled within 7 days with a profit of $18.34 (47.44%) receiving and performance score of 67.77.

Average potential price target upside

of $122.55 (83.02%) on ACET (ADICET BIO).
of $16.5 (98.26%) on IMVT (IMMUNOVANT ).
of $15.72 (15.48%) on BPMC (BLUEPRINT MEDICINES CORP).

ARCT Arcturus Therapeutics Holdings PSTX Poseida Therapeutics ADCT ADC Therapeutics SA IMNM Immunome SRRA Sierra Oncology GOSS Gossamer Bio APLS Apellis Pharmaceuticals NTLA Intellia Therapeutics ROIV Roivant Sciences Ltd XNCR Xencor ACET Adicet Bio BCAB Bioatla ALLO Allogene Therapeutics MRSN Mersana Therapeutics PTGX Protagonist Therapeutics ZYME Zymeworks Common Stock BPMC Blueprint Medicines Corp EDIT Editas Medicine IMVT Immunovant CRGX CARGO Therapeutics, Common Stock KYTX Kyverna Therapeutics, Common Stock ITOS Iteos Therapeutics PGEN Precigen BCRX BioCryst Pharmaceuticals CGON CG Oncology, Common stock MGX Metagenomi, Common Stock RGLS Regulus Therapeutics SR Spire

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Mayank Mamtani (B. RILEY)